{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:36:03Z","timestamp":1777250163892,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44139-7","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T23:52:52Z","timestamp":1777247572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced age increases cancer-specific mortality in bone-only metastatic prostate cancer: a SEER analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Cagatay","family":"Ozsoy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyup","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Tipirdamaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9677-5673","authenticated-orcid":false,"given":"Erhan","family":"Ates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"44139_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345. https:\/\/doi.org\/10.3322\/caac.21871 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"44139_CR2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31, 578\u2013583. https:\/\/doi.org\/10.1053\/hp.2000.6698 (2000).","journal-title":"Hum. Pathol."},{"key":"44139_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.euros.2024.06.006","volume":"66","author":"ME Ahmed","year":"2024","unstructured":"Ahmed, M. E. et al. Survival patterns based on first-site-specific visceral metastatic prostate cancer: are outcomes of visceral metastases the same? Eur. Urol. Open. Sci. 66, 38\u201345. https:\/\/doi.org\/10.1016\/j.euros.2024.06.006 (2024).","journal-title":"Eur. Urol. Open. Sci."},{"key":"44139_CR4","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/cncr.32630","volume":"126","author":"B Bernard","year":"2020","unstructured":"Bernard, B., Burnett, C., Sweeney, C. J., Rider, J. R. & Sridhar, S. S. Impact of age at diagnosis of de novo metastatic prostate cancer on survival. Cancer 126, 986\u2013993. https:\/\/doi.org\/10.1002\/cncr.32630 (2020).","journal-title":"Cancer"},{"key":"44139_CR5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/iju.13535","volume":"25","author":"D Tilki","year":"2018","unstructured":"Tilki, D. et al. Local treatment for metastatic prostate cancer: a systematic review. Int. J. Urol. 25, 390\u2013403. https:\/\/doi.org\/10.1111\/iju.13535 (2018).","journal-title":"Int. J. Urol."},{"key":"44139_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40169-019-0247-4","volume":"8","author":"F Zhao","year":"2019","unstructured":"Zhao, F. et al. Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients. Clin. Transl.  Med. 8, 30. https:\/\/doi.org\/10.1186\/s40169-019-0247-4 (2019).","journal-title":"Clin. Transl. Med."},{"key":"44139_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3857\/roj.2022.00101","volume":"40","author":"\u00c1 S\u00e1nchez-Iglesias","year":"2022","unstructured":"S\u00e1nchez-Iglesias, \u00c1., Morillo-Mac\u00edas, L., Santaf\u00e9-Jim\u00e9nez, V., Ferrer-Albiach, C. & A. & Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience. Radiat. Oncol. J. 40, 192\u2013199. https:\/\/doi.org\/10.3857\/roj.2022.00101 (2022).","journal-title":"Radiat. Oncol. J."},{"key":"44139_CR8","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1002\/cncr.26392","volume":"118","author":"E Scosyrev","year":"2012","unstructured":"Scosyrev, E., Messing, E. M., Mohile, S., Golijanin, D. & Wu, G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 118, 3062\u20133070. https:\/\/doi.org\/10.1002\/cncr.26392 (2012).","journal-title":"Cancer"},{"key":"44139_CR9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.7150\/jca.4192","volume":"4","author":"MR Humphreys","year":"2013","unstructured":"Humphreys, M. R., Fernandes, K. A. & Sridhar, S. S. Impact of age at diagnosis on outcomes in men with castrate-resistant prostate cancer (CRPC). J. Cancer. 4, 304\u2013314. https:\/\/doi.org\/10.7150\/jca.4192 (2013).","journal-title":"J. Cancer"},{"key":"44139_CR10","doi-asserted-by":"publisher","first-page":"e390396","DOI":"10.1200\/edbk_390396","volume":"43","author":"LS Graham","year":"2023","unstructured":"Graham, L. S. et al. Management of prostate cancer in older adults. Am. Soc. Clin. Oncol. Educ. Book. 43, e390396. https:\/\/doi.org\/10.1200\/edbk_390396 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"44139_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/14737140.2022.2098718","volume":"22","author":"JE Rodriguez","year":"2022","unstructured":"Rodriguez, J. E. et al. Immunosenescence, inflammaging, and cancer immunotherapy efficacy. Expert Rev. Anticancer Ther. 22, 915\u2013926. https:\/\/doi.org\/10.1080\/14737140.2022.2098718 (2022).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"44139_CR12","doi-asserted-by":"publisher","first-page":"e0309941","DOI":"10.1371\/journal.pone.0309941","volume":"19","author":"GS Lai","year":"2024","unstructured":"Lai, G. S. et al. Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients. PLoS One. 19, e0309941. https:\/\/doi.org\/10.1371\/journal.pone.0309941 (2024).","journal-title":"PLoS One"},{"key":"44139_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia, G. et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur. Urol. 68, 325\u2013334 (2015).","journal-title":"Eur. Urol."},{"key":"44139_CR14","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","volume":"34","author":"S Halabi","year":"2016","unstructured":"Halabi, S. et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J. Clin. Oncol. 34, 1652\u20131659 (2016).","journal-title":"J. Clin. Oncol."},{"key":"44139_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.eururo.2014.12.026","volume":"68","author":"O Bratt","year":"2015","unstructured":"Bratt, O. et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur. Urol. 68, 53\u201358. https:\/\/doi.org\/10.1016\/j.eururo.2014.12.026 (2015).","journal-title":"Eur. Urol."},{"key":"44139_CR16","doi-asserted-by":"publisher","first-page":"100943","DOI":"10.1016\/j.adro.2022.100943","volume":"7","author":"U Gardner Jr","year":"2022","unstructured":"Gardner, U. Jr, McClelland, S. III & Deville, C. Jr Disparities in the utilization of radiation therapy for prostate cancer in the United States: a comprehensive review. Adv. Radiation Oncol. 7, 100943 (2022).","journal-title":"Adv. Radiation Oncol."},{"key":"44139_CR17","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41391-021-00389-2","volume":"24","author":"DE Lage","year":"2021","unstructured":"Lage, D. E. et al. Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 24, 1181\u20131188. https:\/\/doi.org\/10.1038\/s41391-021-00389-2 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"44139_CR18","doi-asserted-by":"publisher","first-page":"e4636","DOI":"10.1097\/MD.0000000000004636","volume":"95","author":"G Roviello","year":"2016","unstructured":"Roviello, G. et al. Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: a meta-analysis of randomized trials. Medicine 95, e4636 (2016).","journal-title":"Medicine"},{"key":"44139_CR19","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/pros.22716","volume":"73","author":"NA Damaschke","year":"2013","unstructured":"Damaschke, N. A., Yang, B., Bhusari, S., Svaren, J. P. & Jarrard, D. F. Epigenetic susceptibility factors for prostate cancer with aging. Prostate 73, 1721\u20131730. https:\/\/doi.org\/10.1002\/pros.22716 (2013).","journal-title":"Prostate"},{"key":"44139_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.5489\/cuaj.11161","volume":"6","author":"KM Leung","year":"2012","unstructured":"Leung, K. M., Hopman, W. M. & Kawakami, J. Challenging the 10-year rule: the accuracy of patient life expectancy predictions by physicians in relation to prostate cancer management. Can. Urol. Assoc. J. 6, 367\u2013373. https:\/\/doi.org\/10.5489\/cuaj.11161 (2012).","journal-title":"Can. Urol. Assoc. J."},{"key":"44139_CR21","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/j.1464-410X.2007.07130.x","volume":"100","author":"J Walz","year":"2007","unstructured":"Walz, J. et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int. 100, 1254\u20131258 (2007).","journal-title":"BJU Int."},{"key":"44139_CR22","doi-asserted-by":"publisher","first-page":"e0326429","DOI":"10.1371\/journal.pone.0326429","volume":"20","author":"X Zhang","year":"2025","unstructured":"Zhang, X. & Wang, Y. Survival benefit of radical prostatectomy in bone metastatic prostate cancer stratified by disease characteristics: a SEER-based retrospective analysis. PLOS ONE. 20, e0326429. https:\/\/doi.org\/10.1371\/journal.pone.0326429 (2025).","journal-title":"PLOS ONE"},{"key":"44139_CR23","doi-asserted-by":"publisher","first-page":"16697","DOI":"10.1002\/cam4.6292","volume":"12","author":"T Zhai","year":"2023","unstructured":"Zhai, T. et al. The role of cytoreductive radical prostatectomy and lymph node dissection in bone-metastatic prostate cancer: a population-based study. Cancer Med. 12, 16697\u201316706. https:\/\/doi.org\/10.1002\/cam4.6292 (2023).","journal-title":"Cancer Med."},{"key":"44139_CR24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.euf.2017.06.016","volume":"3","author":"T Steuber","year":"2017","unstructured":"Steuber, T. et al. Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study. Eur. Urol. Focus. 3, 646\u2013649. https:\/\/doi.org\/10.1016\/j.euf.2017.06.016 (2017).","journal-title":"Eur. Urol. Focus"},{"key":"44139_CR25","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.3390\/curroncol30020170","volume":"30","author":"T Yanagisawa","year":"2023","unstructured":"Yanagisawa, T. et al. An updated systematic and comprehensive review of cytoreductive prostatectomy for metastatic prostate cancer. Curr. Oncol. 30, 2194\u20132216. https:\/\/doi.org\/10.3390\/curroncol30020170 (2023).","journal-title":"Curr. Oncol."},{"key":"44139_CR26","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353\u20132366. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3 (2018).","journal-title":"Lancet"},{"key":"44139_CR27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boev\u00e9","year":"2019","unstructured":"Boev\u00e9, L. M. S. et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur. Urol. 75, 410\u2013418. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.008 (2019).","journal-title":"Eur. Urol."},{"key":"44139_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","volume":"76","author":"S Burdett","year":"2019","unstructured":"Burdett, S. et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur. Urol. 76, 115\u2013124. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.003 (2019).","journal-title":"Eur. Urol."},{"key":"44139_CR29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl. J. Med. 373, 737\u2013746. https:\/\/doi.org\/10.1056\/NEJMoa1503747 (2015).","journal-title":"N Engl. J. Med."},{"key":"44139_CR30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163\u20131177. https:\/\/doi.org\/10.1016\/s0140-6736(15)01037-5 (2016).","journal-title":"Lancet"},{"key":"44139_CR31","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.urolonc.2014.01.004","volume":"32","author":"CG Rusthoven","year":"2014","unstructured":"Rusthoven, C. G. et al. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol. Oncol. 32, 707\u2013713. https:\/\/doi.org\/10.1016\/j.urolonc.2014.01.004 (2014).","journal-title":"Urol. Oncol."},{"key":"44139_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/jco.2017.75.3921","volume":"36","author":"LC Harshman","year":"2018","unstructured":"Harshman, L. C. et al. Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel. J. Clin. Oncol. 36, 376\u2013382. https:\/\/doi.org\/10.1200\/jco.2017.75.3921 (2018).","journal-title":"J. Clin. Oncol."},{"key":"44139_CR33","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/cncr.30503","volume":"123","author":"B Bernard","year":"2017","unstructured":"Bernard, B. et al. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer 123, 1536\u20131544. https:\/\/doi.org\/10.1002\/cncr.30503 (2017).","journal-title":"Cancer"},{"key":"44139_CR34","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1007\/s00345-021-03720-7","volume":"39","author":"C W\u00fcrnschimmel","year":"2021","unstructured":"W\u00fcrnschimmel, C. et al. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races\/ethnicities. World J. Urol. 39, 3781\u20133787. https:\/\/doi.org\/10.1007\/s00345-021-03720-7 (2021).","journal-title":"World J. Urol."},{"key":"44139_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41391-023-00710-1","volume":"26","author":"SJ Freedland","year":"2023","unstructured":"Freedland, S. J. et al. The impact of race on survival in metastatic prostate cancer: a systematic literature review. Prostate Cancer Prostatic Dis. 26, 461\u2013474. https:\/\/doi.org\/10.1038\/s41391-023-00710-1 (2023).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"44139_CR36","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.1038\/s41598-024-56145-8","volume":"14","author":"Q Chen","year":"2024","unstructured":"Chen, Q. et al. A study on the impact of marital status on the survival status of prostate cancer patients based on propensity score matching. Sci. Rep. 14, 6162. https:\/\/doi.org\/10.1038\/s41598-024-56145-8 (2024).","journal-title":"Sci. Rep."},{"key":"44139_CR37","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.urolonc.2019.04.023","volume":"37","author":"S Knipper","year":"2019","unstructured":"Knipper, S. et al. Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: a population-based study. Urol. Oncol. 37, 702\u2013710. https:\/\/doi.org\/10.1016\/j.urolonc.2019.04.023 (2019).","journal-title":"Urol. Oncol."},{"key":"44139_CR38","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamasurg.2016.2305","volume":"151","author":"RJ Coelen","year":"2016","unstructured":"Coelen, R. J. et al. External validation of the estimation of physiologic ability and surgical stress (E-PASS) risk model to predict operative risk in perihilar cholangiocarcinoma. JAMA Surg. 151, 1132\u20131138 (2016).","journal-title":"JAMA Surg."},{"key":"44139_CR39","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/aje\/kwp194","volume":"170","author":"ME Dupre","year":"2009","unstructured":"Dupre, M. E., Beck, A. N. & Meadows, S. O. Marital trajectories and mortality among US adults. Am. J. Epidemiol. 170, 546\u2013555 (2009).","journal-title":"Am. J. Epidemiol."},{"key":"44139_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s13524-011-0032-5","volume":"48","author":"MS Rendall","year":"2011","unstructured":"Rendall, M. S., Weden, M. M., Favreault, M. M. & Waldron, H. The protective effect of marriage for survival: a review and update. Demography 48, 481\u2013506 (2011).","journal-title":"Demography"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44139-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44139-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44139-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T23:52:52Z","timestamp":1777247572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44139-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44139"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44139-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All analyses and the reporting thereof followed the SEER reporting guidelines. Due to the anonymously coded design of the SEER database, study-specific Institutional Review Board ethics approval and consent to participate were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"13511"}}